Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions

American Journal of Clinical Pathology

Volumn 123, Issue 3, 2005, Pages 360-368

  Davidson, Ben ^a   Xi, Zhijun ^b   Klokk, Tove Irene ^b   Tropé, Claes G ^a   Dørum, Anne ^a   Scheistrøen, Marit ^b   Saatcioglu, Fahri ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

Immunoblotting; Immunohistochemistry; Metastasis; Prognosis; Quantitative RT PCR

Indexed keywords

KALLIKREIN; KALLIKREIN 4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER STAGING; CONTROLLED STUDY; EFFUSION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLID TUMOR; STROMA CELL; SURVIVAL RATE;

EID: 14644394954     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/PTBB5BPCKX8K9V69     Document Type: Article

References (40)

1. Jemal H, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin. 2003;53:5-26.
2. Davidson B, Risberg R, Reich R, et al. Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis. Clin Lab Med. 2003;23:729-754.
3. Yousef GM, Diamandis EP. The new human kallikrein gene family: structure, function, and association to disease. Endocrine Rev. 2001;22:184-204.
4. Clements J, Hooper J, Dong Y, et al. The expanded human kallikrein gene family: genomic organisation, tissue-specific expression and potential functions. Biol Chem. 2001;382:5-14.
5. Kim H, Scorilas A, Katsaros D, et al. Human kallikrein gene 5 (KLK5) expression is an indicator of poor prognosis in ovarian cancer. Br J Cancer. 2001;84:643-650.
6. Magklara A, Scorilas A, Katsaros D, et al. The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic role in ovarian cancer. Clin Cancer Res. 2001;7:806-811.
7. Yousef GM, Kyriakopoulou LG, Scorilas A, et al. Quantitative expression of human kallikrein gene 5 (KLK9) in ovarian cancer: a new independent and favorable prognostic marker. Cancer Res. 2001;61:7811-7818.
8. Luo LY, Katsaros D, Scorilas A, et al. Prognostic value of human kallikrein 10 expression in epithelial ovarian carcinoma. Clin Cancer Res. 2001;7:2372-2379.
9. Luo LY, Katsaros D, Scorilas A, et al. The serum concentration of human kallikrein 10 represents a novel biomarker for ovarian cancer diagnosis and prognosis. Cancer Res. 2003;63:807-811.
10. Hoffman BR, Katsaros D, Scorilas A, et al. Immunofluorometric quantitation and histochemical localisation of kallikrein 6 protein in ovarian cancer tissue: a new unfavourable prognostic biomarker. Br J Cancer. 2002;87:763-771.
11. Diamandis EP, Scorilas A, Fracchioli S, et al. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma. J Clin Oncol. 2003;21:1035-1043.
12. Borgono CA, Fracchioli S, Yousef GM, et al. Favorable prognostic value of tissue human kallikrein 11 (hK11) in patients with ovarian carcinoma. Int J Cancer. 2003;106:605-610.
13. Shvartsman HS, Lu KH, Lee J, et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol Oncol. 2003;90:44-50.
14. Dong Y, Kaushal A, Brattsand M, et al. Differential splicing of KLK5 and KLK7 in epithelial ovarian cancer produces novel variants with potential as cancer biomarkers. Clin Cancer Res. 2003;9:1710-1720.
15. Yousef GM, Polymeris ME, Yacoub GM, et al. Parallel overexpression of seven kallikrein genes in ovarian cancer. Cancer Res. 2003;63:2223-2227.
16. Kishi T, Grass L, Soosaipillai A, et al. Human kallikrein 8, a novel biomarker for ovarian carcinoma. Cancer Res. 2003;63:2771-2774.
17. 1-antichymotrypsin. Clin Chem. 2003;49:746-751.
18. Nelson PS, Gan L, Fergusson C, et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A. 1999;96:3114-3119.
19. Yousef GM, Obiezu CV, Luo LY, et al. Prostase/KLK-L1 is a new member of the human kallikrein gene family, is expressed in prostate and breast tissues, and is hormonally regulated. Cancer Res. 1999;59:4252-4256.
20. Korkmaz KS, Korkmaz CG, Pretlow TG, et al. Distinctly different gene structure of KLK4/KLK-L1/prostase/ARM1 compared with other members of the kallikrein family: intracellular localization, alternative cDNA forms, and regulation by multiple hormones. DNA Cell Biol. 2001;20:435-445.
21. Stephenson SA, Verity K, Ashworth LK, et al. Localization of a new prostate-specific antigen-related serine protease gene, KLK4, is evidence for an expanded human kallikrein gene family cluster on chromosome 19q13.3-13.4. J Biol Chem. 1999;274:23210-23214.
22. Obiezu CV, Soosaipillai A, Jung K, et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem. 2002;48:1232-1240.
23. Day CH, Fanger GR, Retter MW, et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene. 2002;21:7114-7120.
24. Obiezu CV, Scorilas A, Katsaros D, et al. Higher human kallikrein gene 4 (KLK4) expression indicates poor prognosis of ovarian cancer patients. Clin Cancer Res. 2001;7:2380-2386.
25. Dong Y, Kaushal A, Bui L, et al. Human kallikrein 4 (KLK4) is highly expressed in serous ovarian carcinomas. Clin Cancer Res. 2001;7:2363-2371.
26. Davidson B, Risberg B, Kristensen G, et al. Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies: evaluation of five epithelial markers. Virchows Arch. 1999;435:43-49.
27. Davidson B, Berner A, Nesland JM, et al. Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and sialyl Tn antigens expression in effusions. Hum Pathol. 2000;31:1081-1087.
28. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol. 2001;25:1405-1412.
29. Young RH, Clement PB, Scully RE. Surface epithelial-stromal tumors. In: Sternberg SS, Antonioli DA, Carter D, et al, eds. Diagnostic Surgical Pathology. Vol 2. Philadelphia, PA: Lippincott Williams & Wilkins; 1999:2319-2382.
30. Xi Z, Klokk TI, Korkmaz K, et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res. 2004;64:2365-2370.
31. Akahira JI, Yoshikawa H, Shimizu Y, et al. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study. Gynecol Oncol. 2001;81:398-403.
32. Davidson B, Reich R, Berner A, et al. Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer. 2001;37:2040-2049.
33. Davidson B, Reich R, Kopolovic J, et al. Interleukin-8 and vascular endothelial growth factor mRNA levels are down-regulated in ovarian carcinoma cells in serous effusions. Clin Exp Metastasis. 2002;19:135-144.
34. Davidson B, Goldberg I, Kopolovic J, et al. Expression of angiogenesis-related genes in ovarian carcinoma: a clinicopathologic study. Clin Exp Metastasis. 2000;18:501-507.
35. Davidson B, Reich R, Goldberg I, et al. Ets-1 mRNA expression is a novel marker of poor survival in ovarian carcinoma. Clin Cancer Res. 2001;7:551-557.
36. Davidson B, Risberg B, Goldberg I, et al. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome. Am J Surg Pathol. 2001;25:1493-1500.
37. Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma. Clin Exp Metastasis. 2003;20:161-169.
38. Davidson B, Goldberg I, Gotlieb WH, et al. High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis. 1999;17:799-808.
39. Davidson B, Goldberg I, Gotlieb WH, et al. PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma. Clin Cancer Res. 2003;9:1412-1419.
40. Elenbaas B, Weinberg RA. Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res. 2001;264:169-184.